1. Scrip
  2. >>Business

Pfizer/Celltrion Prep For October Inflectra Launch

 
• By Donna Young

With Celltrion shipping the first batch of its biosimilar Inflectra (infliximab-dyyb) and a stipulation agreement with Johnson & Johnson, Pfizer is set to launch the product on Oct. 3 – six months after it was approved in the US.

It looks like an Oct. 3 go for Pfizer Inc. and its partner Celltrion Inc. to launch their biosimilar Inflectra (infliximab-dyyb) after reports surfaced the first batch of the drug had been shipped and new court documents revealed the companies had entered into a new agreement with Johnson & Johnson unit Janssen Biotech Inc. to clear the way for US marketing.

Inflectra is a biosimilar version of J&J's blockbuster tumor necrosis factor Remicade.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream

 
• By Mandy Jackson

Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.

J&J Plans Educational Push After Darzalex Smoldering Myeloma Approval

 
• By Alaric DeArment

The FDA approved the anti-CD38 monoclonal antibody, a mainstay of multiple myeloma for a decade, for high-risk smoldering disease.

Lilly/Novo Get Priority Reviews For Lowering Drug Prices

 
• By Jessica Merrill

Novo Nordisk’s high-dose semaglutide for obesity and Lilly’s oral obesity candidate orforglipron were given priority review vouchers by the US Food and Drug Administration.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

More from Scrip

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid

 
• By Kevin Grogan

Even with Innosera's sweetened offers and a boardroom recommendation, the proposed acquisition could not clear the minimum 66.67% shareholder approval level.

Centessa’s Sleep Disorder Drug Shows Broad Potential But Faces Tough Competition

 
• By Sushmita Panda

Pivotal data next year will be key for the early-stage biotech as analysts remain divided on ORX750's potential.